Detalle Publicación


Multitarget approach for the treatment of Alzheimer's disease: inhibition of phosphodiesterase 9 (PDE9) and histone deacetylases (HDACs) covering diverse selectivity profiles

Autores: Rabal, O. (Autor de correspondencia); Sanchez-Arias, J. A.; Cuadrado Tejedor, María del Mar; de Miguel, I.; Pérez González, Marta; Garcia-Barroso, C. ; Ugarte, A.; Estella Hermoso de Mendoza, Ander; Sáez de Blas, Elena; Espelosín Azpilicueta, María; Ursua, S.; Tan, H. Z.; Wu, W. ; Xu, M. S.; Pineda Lucena, Antonio; García Osta, Ana María; Oyarzabal Santamarina, Julen
ISSN: 1948-7193
Volumen: 10
Número: 9
Páginas: 4076 - 4101
Fecha de publicación: 2019
Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacological tool compounds for assessing the implications of these two targets in Alzheimer's disease (AD). These novel inhibitors were designed taking into account the key pharmacophoric features of known selective PDE9 inhibitors as well as privileged chemical structures, bearing zinc binding groups (hydroxamic acids and ortho-amino anilides) that hit HDAC targets. These substituents were selected according to rational criteria and previous knowledge from our group to explore diverse HDAC selectivity profiles (pan-HDAC, HDAC6 selective, and class I selective) that were confirmed in biochemical screens. Their functional response in inducing acetylation of histone and tubulin and phosphorylation of cAMP response element binding (CREB) was measured as a requisite for further progression into complete in vitro absorption, distribution, metabolism and excretion (ADME) and in vivo brain penetration profiling. Compound 31b, a selective HDAC6 inhibitor with acceptable brain permeability, was chosen for assessing in vivo efficacy of these first-in-class inhibitors, as well as studying their mode of action (MoA).